In contrast, while MED1 expression is downregulated and inversely correlated with the expression of metastasis-related genes in melanoma (15), lung cancer (16, 17), and bladder cancer (18), enhanced MED1 activity has been reported in prostate and breast cancer, likely due to its function as a hub for nuclear hormone receptors (18, 19). Here, MED1 is linked to breast cancer.